Compagnie Lombard Odier SCmA Cuts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Compagnie Lombard Odier SCmA lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 87.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,000 shares of the biotechnology company’s stock after selling 57,000 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Aurinia Pharmaceuticals were worth $72,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AUPH. CWM LLC raised its position in Aurinia Pharmaceuticals by 247.7% during the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 8,180 shares in the last quarter. FMR LLC raised its holdings in shares of Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Aurinia Pharmaceuticals in the 4th quarter worth approximately $108,000. China Universal Asset Management Co. Ltd. lifted its position in Aurinia Pharmaceuticals by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after buying an additional 10,700 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Aurinia Pharmaceuticals by 172.9% in the third quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock worth $235,000 after buying an additional 20,324 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Trading Down 2.3 %

NASDAQ AUPH opened at $7.79 on Friday. The firm has a market cap of $1.12 billion, a PE ratio of -51.93 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The stock has a 50-day moving average of $8.52 and a 200-day moving average of $7.61. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.